Sarah S Walter

US Patent:

20070141040, Jun 21, 2007

Filed:

Sep 19, 2006

Appl. No.:

11/524350

Inventors:

Leon Chen - Belmont CA, US
Derek MacLean - Los Altos CA, US
Sarah Walter - Redwood City CA, US

International Classification:

A61K 38/54
C07H 21/04
C12P 21/06
C12N 9/12

US Classification:

424094200, 424094500, 435069100, 435194000, 435320100, 435325000, 536023200

Abstract:

The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the Vdomain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner. The peptides can be used to inhibit angiogenesis and/or vascular permeability. The peptides can be used to treat subjects having, for example, cancer, diabetic blindness, macular degeneration, rheumatoid arthritis, or psoriasis.

US Patent:

20090023652, Jan 22, 2009

Filed:

Nov 16, 2007

Appl. No.:

11/941857

Inventors:

Gregory Bell - Tiburon CA, US
Sarah Walter - Redwood City CA, US
Felix Karim - Walnut Creek CA, US

International Classification:

A61K 38/00
C07K 14/00
C07K 7/00
A61P 19/00

US Classification:

514 12, 514 18, 514 17, 514 16, 514 15, 514 14, 514 13, 530330, 530329, 530328, 530327, 530326, 530325, 530324

Abstract:

The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

US Patent:

20110098224, Apr 28, 2011

Filed:

Oct 12, 2010

Appl. No.:

12/902569

Inventors:

Leon E. Chen - Belmont CA, US
Derek MaClean - Los Altos CA, US
Sarah Walter - Redwood City CA, US

International Classification:

A61K 38/02
C07K 2/00
C07K 7/06
C07K 7/08
C07K 14/00
C12N 9/99
A61P 35/00
A61P 9/00

US Classification:

514 133, 530300, 530329, 530328, 530327, 530326, 530325, 514 11, 435184

Abstract:

The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner. The peptides can be used to inhibit angiogenesis and/or vascular permeability. The peptides can be used to treat subjects having, for example, cancer, diabetic blindness, macular degeneration, rheumatoid arthritis, or psoriasis.

US Patent:

20040018528, Jan 29, 2004

Filed:

May 19, 2003

Appl. No.:

10/440464

Inventors:

Alyssa Morimoto - San Mateo CA, US
Samuel DePrimo - Palo Alto CA, US
Anne-Marie O'Farrell - Menlo Park CA, US
Beverly Smolich - Mountain View CA, US
William Manning - Redwood City CA, US
Sarah Walter - Redwood City CA, US
James Schilling - San Mateo CA, US
Julie Cherrington - San Francisco CA, US

Assignee:

Sugen, Inc.

International Classification:

C12Q001/68
G01N033/53

US Classification:

435/006000, 435/007100

Abstract:

The present invention describes novel methods that measure in a mammal the level of at least one biomarker, such as a protein and/or mRNA transcript. Based on the level of at least one biomarker in a mammal exposed to a test compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to a test compound, the ability of the test compound to inhibit tyrosine kinase activity can be determined. The invention also relates to novel methods, wherein a change in the level of at least one biomarker in a mammal exposed to a compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to the compound, indicates whether the mammal is being exposed to, or is experiencing or will experience a therapeutic or toxic effect in response to, a compound that inhibit tyrosine kinase activity.

US Patent:

20200377581, Dec 3, 2020

Filed:

Dec 12, 2019

Appl. No.:

16/712494

Inventors:

- Jona, CH
Sarah Walter - Redwood City CA, US
Henry Stern - Woodside CA, US
Michael Chang - Portola Valley CA, US

International Classification:

C07K 16/18
A61K 45/06

Abstract:

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

US Patent:

20200331991, Oct 22, 2020

Filed:

Nov 7, 2019

Appl. No.:

16/676988

Inventors:

- Jone, CH
Sarah Walter - Redwood City CA, US
Henry Stern - Woodside CA, US
Michael Chang - Portola Valley CA, US

International Classification:

C07K 16/18

Abstract:

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

US Patent:

20190068667, Feb 28, 2019

Filed:

Oct 30, 2018

Appl. No.:

16/175195

Inventors:

- Mountain View CA, US
Ali Nadaff - Cupertino CA, US
Michael Jon Sundermeyer - Palo Alto CA, US
Rishi Chandra - Los Altos CA, US
John Affaki - San Jose CA, US
Sarah Walter - San Francisco CA, US
Rob McCool - Menlo Park CA, US
Majd Bakar - San Jose CA, US

International Classification:

H04L 29/06
A63F 13/79
A63F 13/23
A63F 13/355
A63F 13/352
A63F 13/335
A63F 13/26
A63F 13/428

Abstract:

In one general aspect, a method can include receiving, at a server computing device, a launch request to launch and stream media content pertaining to a game session, the launch request being provided by a mobile device, selecting, using the launch request, a media host configured to stream the media content, verifying a user associated with the mobile device and launching the game session for streaming to the user on a device other than the mobile device. In addition, the method can include during the game session and while streaming the media content, receiving a plurality of real time control requests from the mobile device, and executing the control request by compositing, in real time, the at least one change and the media content and to produce a composite display and transmitting, to the device other than the mobile device, the encoded composite display for streaming in real time.

US Patent:

20190031745, Jan 31, 2019

Filed:

Jan 25, 2018

Appl. No.:

15/879900

Inventors:

- Jona, CH
Sarah Walter - Redwood City CA, US
Henry Stern - Woodside CA, US
Michael Chang - Portola Valley CA, US

International Classification:

C07K 16/18

Abstract:

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.